MBX-2982 (SAR-260093) is a novel, potent, selective and orally bioavailable G protein-coupled receptor 119 (GPR119) agonist with the potential for treating type 2 diabetes. Preclinical data indicate that MBX-2982 is a potent selective orally -active GPR119 agonist that functions through a unique dual mechanism of action. First, it acts directly on the beta cell to increase insulin secretion. In addition, MBX-2982 stimulates release of the incretin GLP-1 from the gut. This dual action is unique and may offer improved glucose homeostasis over existing diabetes therapies, with potential for weight loss and improved islet health.

纯度：≥98%

CAS：1037792-44-1